Donald J Trump (R) Sells Repligen (RGEN) Stock

Donald Trump sold Repligen shares worth between $1,001 and $15,000 on May 22, 2026.

By EarningsIQ Research Desk · Published Jul 1, 2026, 11:01 AM EDT · Updated Jul 1, 2026, 12:01 PM EDT

Reviewed by automated data checks against the source filing. How we make and check alerts

Donald J Trump (R) sold between $1,001 and $15,000 of Repligen Corporation ($RGEN) stock on May 22, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed July 1, 2026.

Since the trade, $RGEN is up 7.7% after 1 week, up 10.0% after 1 month and up 52.5% to date (from the $115.06 close on May 22, 2026).

Filer Information

Name:: Donald J Trump (R)
Status:: Member
Party:: republican

Filing Information

Filing Type:: Periodic Transaction Report
Filing Year:: 2026
Filing Date:: Jul 1, 2026

Schedule B: Transactions

Asset	Transaction	Date	Amount
Repligen Corporation ($RGEN)	Sell	May 22, 2026	$1,001 - $15,000

Summary of the filed report, not the original document.

RGEN Repligen Corporation

$175.42 +6.74% year to date

Daily close · Oct 16, 2026

Key Points

Donald Trump sold shares of Repligen Corporation on May 22, 2026, valued between $1,001 and $15,000.
Repligen, trading at $136.44, has a market cap of $7.70 billion and a forward P/E of 53.6.
Analysts maintain a 'buy' consensus with a mean price target of $176.11 for Repligen.

Get $RGEN trade alerts by text

We text you when insiders, Congress or big funds trade $RGEN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Repligen Corporation alert may contain errors. Disclosures

On May 22, 2026, Donald Trump, associated with the Republican party, sold shares of Repligen Corporation (NASDAQ: RGEN). The transaction was valued between $1,001 and $15,000 according to a report filed on July 1, 2026. These transactions are part of periodic disclosures under the STOCK Act.

Congressional trading track record

Donald J Trump vs. the S&P 500

YTD return +5.95% hypothetical

All-time return +6.08% S&P 500 +8.05%

vs. S&P 500 -1.97% behind the index

Hypothetical returns from Donald J Trump's disclosed trades, not real profit or advice. How we model this.

Repligen Corporation Stock Down 22.9%

Shares of Repligen Corporation traded near $136.44 as of Wednesday. The company, which operates in the healthcare sector, specifically in medical instruments and supplies, has a market capitalization of approximately $7.70 billion. It holds a P/E ratio of 149.9 and a forward P/E of 53.6, indicating expectations of future earnings growth. Repligen's stock has seen a 52-week range between $100.99 and $175.77. The company maintains a strong financial position with a current ratio of 9.2 and a quick ratio of 7.5.

Recent Earnings

Repligen reported revenues of $763.3 million, reflecting a growth rate of 14.8%. The company achieved an earnings per share (EPS) of $0.91, with a net margin of 6.7% and a return on equity (ROE) of 2.5%. The next earnings report is expected on August 4, 2026.

Insider Buying and Selling at Repligen Corporation

Recent insider activity at Repligen includes a planned sale by CFO Jason Garland, who sold 733 shares at an average price of $145 on June 25, 2026. Conversely, several insiders, including Carrie Eglinton Manner, Nicolas Barthelemy, Martin Madaus, and Glenn Muir, bought shares on May 14, 2026, although the transaction details were not disclosed.

Analysts Set New Price Targets

Analysts continue to show confidence in Repligen. On June 3, 2026, HSBC maintained its 'buy' rating with a price target of $150. Wolfe Research assumed coverage with a 'buy' rating and a $145 target on June 2, 2026. RBC Capital reinstated a 'buy' rating with a $160 target on May 15, 2026. The consensus among 19 analysts is a 'buy' recommendation, with a mean target price of $176.11.

About Repligen Corporation

Repligen Corporation, headquartered in Waltham, Massachusetts, is a life sciences company specializing in bioprocessing technologies and systems. It offers a wide range of products, including chromatography systems, filtration products, and process analytics tools, catering to life sciences, biopharmaceutical, and diagnostics sectors. The company is led by CEO Olivier Loeillot and employs around 2,000 people.

Bottom Line

Donald Trump's sale of Repligen shares is part of routine disclosures required for public officials. Repligen remains a notable player in the healthcare industry, with a strong market position and positive analyst outlook. Investors often track such transactions for insights into potential market movements, though 13F filings and STOCK Act disclosures are backward-looking and may not reflect current positions.